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Negative symptoms in schizophrenia: The prevailing challenges 
Abstract 
Although many advances in the understanding and treatment of schizophrenia have been made many 
challenges still remain. Most notably is the lack of understanding pertaining to the negative symptoms 
dimension of schizophrenia and the treatment of such symptomology? Primary negative symptoms 
affect 20-40% of individuals with schizophrenia and are associated with the greatest impacts upon 
functional impairment and quality of life. A qualitative review of the prevailing challenges related to the 
nature, assessment and treatment of negative symptoms was conducted. The current literature in each of 
the aforementioned areas pertaining to primary negative symptoms was reviewed with a focus upon the 
key challenges and directions for future research. The results of the qualitative review indicate that the 
construct of negative symptoms requires further delineation and recent work in the area of the 
assessment of negative symptoms necessitates further development. In regards to the treatment of 
negative symptoms no definitive directions are espoused due to the extent of the dearth of knowledge in 
the area as highlighted in the discussion. The area of negative symptoms research requires multi-
disciplinary collaborative research to address the major challenges to the understanding, assessment and 
treatment of negative symptoms in schizophrenia to improve the quality of life and functional outcomes 
of those with primary negative symptoms. 
Keywords 
prevailing, challenges, schizophrenia, negative, symptoms 
Publication Details 
Pai, N. & Vella, S. C. (2015). Negative symptoms in schizophrenia: The prevailing challenges. Nitte 
University Journal of Health Science, 5 (2), 104-115. 
This journal article is available at Research Online: https://ro.uow.edu.au/smhpapers/3114 
104
NUJHS Vol. 5, No.2,  2015, ISSN 2249-7110June
Nitte University Journal of Health Science
Keywords : Schizophrenia, Negative Symptoms, Assessment
& Treatment - Shae-Leigh C Vella
Introduction :
Over the past decade or so several scientific advances have 
been made in the fields of genetics, biology and 
pharmacology in relation to the epidemiology, diagnosis 
and treatment of schizophrenia and related disorders. 
Some examples include the exploration of biomarkers and 
candidate genes in the susceptibility and development of 
schizophrenia (DeRosse et al., 2008; Javitt, Spencer, Thaker, 
Winterer, & Hajos, 2008; Pogue-Geile & Yokley, 2010), the 
identification of structural and functional brain 
abnormalities (Karlsgodt, Sun, & Cannon, 2010), and the 
trial of promising new medications in animal models and 
humans (Patil et al., 2007). 
None the less, major 
challenges remain. 
A r g u a b l y  t h e  m o s t  
significant and pervasive 
challenge to the field 
relates to the dearth of 
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Abstract :
Although many advances in the understanding and treatment of schizophrenia have been made many challenges still remain. Most 
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assessment of negative symptoms necessitates further development. In regards to the treatment of negative symptoms no definitive 
directions are espoused due to the extent of the dearth of knowledge in the area as highlighted in the discussion. The area of negative 
symptoms research requires multi-disciplinary collaborative research to address the major challenges to the understanding, 
assessment and treatment of negative symptoms in schizophrenia to improve the quality of life and functional outcomes of those with 
primary negative symptoms.  
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knowledge pertaining to negative symptoms in 
schizophrenia spectrum disorders. Negative symptoms in 
schizophrenia are defined as a deficit or diminution of 
normal functioning (Blanchard &Cohen, 2006; Stahl & 
Buckley, 2007); historically negative symptomology were 
conceptualised as the core of the disorder (Bleuler, 1978; 
Kraepelin, 2009). However since early conceptualisations 
negative symptoms have long been the neglected 
symptom dimension in the field (Kaiser, Heekeran & Simon, 
2011; Rector, Beck & Stolar, 2005; Turkington & Morrison, 
2012) despite the significant functional impairments that 
are associated with such symptomology. 
Schizophrenia in itself is a chronic and debilitating illness 
that results in high levels of disability and functional 
impairment (Makinen, Miettunen, Isohanni & Koponen, 
2008); with approximately 20-40% of individuals 
diagnosed with schizophrenia experiencing persistent and 
enduring negative symptoms (Makinen, Miettunen, 
Isohanni & Koponen, 2008). It is these individuals with 
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enduring negative symptoms that are known to have 
significantly poorer functional outcomes, higher levels of 
long-term morbidity and greater familial burden than 
those with prominent positive symptoms (Bowie, 
Reichenberg, Patterson, Heaton, & Harvey, 2006; Kaiser, 
Heekeran & Simon, 2011; Kirkpatrick, Fenton, Carpenter & 
Marder, 2006; Milev, Ho, Arndt, & Andreasen, 2005; 
Rabinowitz et al., 2012). Further negative symptoms are 
often more stable and enduring over time than positive 
symptoms (Velligan et al., 2006). Thus negative symptoms, 
such as the inability to experience pleasure, social 
withdrawal, poverty of speech and decreased motivation 
are often considered a major unmet need in health services 
and medical research (Alphs, 2006).
The National Institute of Mental Health (NIMH) released a 
consensus statement on negative symptoms several years 
ago highlighting areas pertaining to negative 
symptomology that require further research, clarification 
and consensus (Kirkpatrick et al., 2006).  Seven years on 
from the release of the consensus statement more work is 
required in the area of negative symptomology in order to 
capitalise and advance upon the agreement and 
developments spawned by the NIMH consensus statement 
on negative symptoms (Kirkpatrick et al., 2006).
Therefore this paper seeks to highlight key challenges that 
remain in negative symptom research and identify 
imperatives for future research. The paper will firstly briefly 
highlight the heterogeneous nature of schizophrenia in 
general and the associated challenges. Before highlighting 
the challenges specific to negative symptomology as they 
pertain to the nature of negative symptoms as well as their 
assessment and treatment. Each section will conclude with 
recommendations for future research. With such research 
having the potential to facilitate more effective 
assessment, treatment and management of negative 
symptoms in schizophrenia and thus the ability to 
significantly improve the quality of life of the 20-40% of 
individuals with schizophrenia that experience persistent 
and enduring negative symptoms. 
Brief Overview of the Heterogeneous Nature of 
Schizophrenia Generally
Schizophrenia itself is a complex and heterogeneous 
disorder; with positive symptomology, negative 
symptomology, affective symptomology, disorganization 
and cognitive deficits all interacting to add to the overall 
complexity associated with the challenges pertaining to 
negative symptoms specifically. The complexity of this 
association is illustrated in Figure 1 below; in this figure it is 
apparent that all five dimensions overlap with each other 
as well as intersect altogether.
Thus the complexity of schizophrenia as highlighted in the 
diagram above is associated with several prevailing 
challenges; these challenges are summarised in Box 1 
below. The first challenge pertains to the nature of the 
psychopathology associated with schizophrenia being truly 
dimensional in nature; however the nomenclature 
attempts to categorise and award pseudo boundaries to 
the symptomology. Similarly the second challenge relates 
to the issues associated with quantifying a phenomenon 
that is in fact qualitative in nature; that is all individuals' 
exper ience  sch izophrenia  d i f ferent ly  making  
quantification of the dimensions problematic. 
The third challenge pertains to the lack of a specific 
treatment goal or target for treatment in the treatment of 
schizophrenia. That is psychiatric diagnoses are symptom 
based as such treatment is symptom based; hence the true 
underlying dimension is not being targeted in treatment.  
The last challenge noted above is the false assumption that 
schizophrenia results from a single aetiology rather than as 
a result of multiple aetiologies. Or distinctive aetiologies 
associated with each of the dimensions outlined above. 
These challenges; reflective of the nature of schizophrenia 
and our understanding of the disorder further complicate 
the assessment and treatment of schizophrenia generally 
as well as impacting upon the negative symptom 
dimension specifically.
Box 1. The Prevailing Challenges in Schizophrenia
The Challenges
Dimensional versus Categorical Nature of Schizophrenia
Quantifying a Phenomenon that is Truly Qualitative in Nature
Lack of  Specific Treatment Goal in Schizophrenia
The Pseudo-Assumption of a Single Aetiology of Schizophrenia
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Figure 1. The Heterogeneous Nature of Schizophrenia Figure 2. The Inter-Relatedness of the Key Challenges
in Negative Symptom Research
Negative Symptoms: The Key Challenges
The following section summarises the current state of 
knowledge pertaining to negative symptoms; highlighting 
the key challenges and gaps in the area. Broadly there are 
three key challenges: firstly; what is the nature of negative 
symptoms, secondly; challenges pertaining to the 
assessment of negative symptoms and thirdly; challenges 
relating to the treatment of negative symptoms. Similarly 
to the nature of schizophrenia in general, these challenges 
pertaining specifically to negative symptoms are not 
independent with each of the aforementioned challenges 
being inter-related and as such hindering progress in each 
of the respective areas. The inter-relatedness of these 
challenges is illustrated in Figure 2 below. Further it is the 
author's viewpoint that the abovementioned order 
accorded to the key challenges in negative symptoms 
research highlights the hierarchical nature in which these 
would most effectively be addressed with research in each 
area informing research within the subsequent domains.
What is the Nature of Negative Symptoms?
A lack of consensus and consistency in the negative 
symptomology construct has continued to hinder research 
efforts in the area. Fundamentally there remains 
uncertainties in the symptoms' that comprise the negative 
symptom dimension (American Psychiatric Association, 
2000; Kirkpatrick, 2006; Arango & Carpenter, 2011). 
With the DSM-IV-TR (American Psychiatric Association, 
2000) listing affective flattening (blunted affect), alogia and 
avolition as negative symptoms with anhedonia noted as 
an associated feature of schizophrenia. In contrast Arango 
and Carpenter (2011) ascertain that asociality and apathy 
along with anhedonia are commonly also acknowledged to 
be negative symptoms in addition to affective flattening 
(blunted affect), alogia and avolition. Kirkpatrick and 
colleagues (2006) in the NIMH consensus statement on 
negative symptoms agreed that asociality, blunted affect, 
alogia, anhedonia and avolition currently constitute the 
negative symptom dimension. These symptoms 
acknowledged by the NIMH consensus statement on 
negative symptoms are defined in Table 1 below.
Table 1. Definitions of Negative Symptoms
Negative Symptom Definition*
Blunted Affect Reduced emotional expression and 
expressiveness.
Alogia Poverty of speech or poverty of content of 
speech.
Avolition Lack of volitional action.
Asociality Lack of interest in social contact and 
experiences.
Anhedonia Inability to experience pleasure.
*Definitions of symptoms' in the table above are derived from 
Arango and Carpenter (2011).
In addition to the symptoms that comprise the negative 
symptom dimension of schizophrenia there are also 
questions pertaining to the factor structure of the 
construct (Blanchard & Cohen, 2006; Kirkpatrick & Fisher, 
2006). For example is the construct of negative symptoms 
in schizophrenia uni-dimensional or multi-dimensional in 
nature (Blanchard & Cohen, 2006; Kirkpatrick & Fisher, 
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2006).   If the construct is multi-dimensional what is the 
factor structure that underlies the construct (Blanchard & 
Cohen, 2006; Kirkpatrick & Fisher, 2006). 
Recently Messinger and colleagues (2011) in a theoretical 
review suggested that the symptoms of avolition and 
affective deficits constitute the negative symptom domain. 
Similarly Horan and colleagues' (2011) found a two factor 
solution for a recently developed measure of negative 
symptoms; the Clinical Assessment Interview for Negative 
Symptoms (CAINS). Specifically the factor structure could 
be broadly distinguished between experiential and 
expressive items (Horan et al., 2011). Furthermore in light 
of the aforementioned issues further clarification of the 
nosology of negative symptomology is also needed 
(Linscott & van Os, 2006; Parnas, 2011). As such 
clarification is paramount to not only diagnosis, but also; to 
research in general and more importantly the meaningful 
interpretation and translation of results of empirical 
studies into clinical practice (Erhart, Marder & Carpenter, 
2006). 
In addition to the aforementioned issues and lack of 
consensus pertaining to negative symptomology some 
researchers have even conjectured that the disease entity 
(sch izophrenia)  marked by  pr imary  negat ive  
symptomology is not simply a distinct dimension rather it 
indicates the presence of a separate disease; not 
schizophrenia (Carpenter, 2006; Carpenter, 2007; Kaiser, 
Heekeren & Simon, 2011). As factor analytic research 
commonly supports the notion of schizophrenia spectrum 
disorders being multi-dimensional in nature however 
inconsistencies to the factor structure of schizophrenia in 
general remain (Lindenmayer, Grochowski & Hyman, 1995; 
Toomey et al., 1997; Peralta & Cuesta, 2001; Blanchard & 
Cohen, 2006). 
Similarly others have questioned the definition of negative 
symptoms (Messinger et al., 2011). With Messinger and 
colleagues (2011) highlighting that defining negative 
symptoms as a diminution or deficit of normal functioning 
as problematic due to the current understanding of 
cognitive processes in schizophrenia. However it should be 
noted that this is the definition commonly utilised and 
endorsed by the NIMH consensus statement on negative 
symptoms (Kirkpatrick et al., 2006) and as such the 
definition adopted in this article. However, future 
questioning and reframing of the definition based upon 
strong empirical support may be needed. 
Thus it is clearly apparent that there remains a general lack 
of consensus pertaining to the nature of negative 
symptoms in schizophrenia. Table 2 below highlights some 
of the key challenges in the area and the actions that are 
required as well as the potential implications of such 
research. Future research should seek to delineate and 
validate an empirically founded definition of negative 
symptoms as well as clarifying the nosology of negative 
symptoms. Further the symptoms that comprise the 
negative symptom domain and the factor structure of the 
negative symptom domain also require clarification, 
delineation and consensus.  Specifically, Erhart, Marder 
and Carpenter (2006) recommend the delineation of 
whether negative symptoms are homogenous or 
heterogeneous as well as categorical or dimensional. Such 
work will greatly benefit the advancement of research 
endeavours aimed at developing and improving the 
assessment and treatment of negative symptomology in 
schizophrenia. 
Table 2. The Nature of Negative Symptoms: Challenges, Actions Required & Implications
Challenge Research / Action Required Implications
Consistency in the definition of the
domains of negative symptoms Statement of Negative Symptom
domains (Kirkpatrick et al., 2006) research into clinical practice more straight 
forward.
Nomenclature for diagnosis that
encompasses these domains
Adoption of the NIMH Consensus Consistency in research & clinical practice; 
assisting with making the translation of 
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Challenge Research / Action Required Implications
Identifying the true boundary
conditions of the negative domains specified by Kirkpatrick conditions and structure of the construct 
symptom construct et al. (2006) are the true boundaries has the potential to advance assessment 
of the negative symptom construct. and treatment.
Theorising as to the structure of the
negative symptom construct.
Consensus on the definition of Research to clarify whether the current Clarification and delineation of the
negative symptoms definition of negative symptoms is flawed relationship between negative symptoms
due to our emerging understanding of and cognition in schizophrenia has the 
cognitive problems in schizophrenia potential to lead to treatment interventions
(Messinger et al., 2011). for both issues. As well as the potential to 
inform early intervention strategies.
Research to ascertain whether the five An understanding of the true boundary 
The Assessment of Negative Symptoms
The very nature of negative symptoms makes assessment 
difficult for researchers and clinicians alike. Negative 
symptoms are insidious and represent an absence or 
reduction of usual behaviours often making them difficult 
for clinicians to recognise and diagnose  (Buckley & Stahl, 
2007). Moreover negative symptoms can also impede the 
individual's ability to communicate their inner experiences 
and psychopathology (Fanous et al., 2012). Likewise there 
are also problems associated with detecting improvements 
in negative symptomology over time (Stahl & Buckley, 
2007). 
Negative symptoms are not uni-factorial in origin (Toomey 
et al., 1997), nor are they commonly considered to 
represent a homogenous entity (Blanchard & Cohen, 
2006). Thus the distinction between primary negative 
symptoms; those that intrinsically reflect the core 
symptoms of the disorder itself, and secondary negative 
symptoms; those that result from other factors such as the 
effects of antipsychotic treatment, positive symptoms, 
extrapyramidal symptoms, depression or environmental 
under-stimulation remains elusive (Flaum & Andreasen, 
1995; Messinger et al., 2011). Further few have used 
diagnostic and assessment scales to attempt to distinguish 
between primary and secondary negative symptoms. Thus, 
it is often unclear in antipsychotic outcome studies the 
origin of the negative symptoms that are responding (or 
not responding) to treatment (Murphy, Chung, Park, & 
McGorry, 2006). 
The assessment of negative symptoms is intimately linked 
to the conceptualisation of the nature of negative 
symptoms (as discussed in the section above) with the 
nature of negative symptoms being reflective of how they 
are assessed. Factor analysis of two of the most commonly 
utilised instruments for the assessment of negative 
symptoms as suggested by Erhart, Marder and Carpenter 
(2006); the Scale for the Assessment of Negative 
Symptoms (SANS: Andreasen 1982; Andreasen, 1983) and 
the Schedule for Deficit Syndrome (SDS: Kirkpatrick et al., 
1989) indicate that they both assess more than a single 
factor. Suggesting that negative symptoms are multi-
dimensional in nature; well at least how they are 
conceptualised and measured by the two aforementioned 
instruments (Erhart, Marder & Carpenter, 2006). 
Further the shortcomings of another commonly utilised 
instrument for the assessment of negative symptoms the 
Positive and Negative Syndrome Scale (PANSS: Kay, Fiszbein 
& Opler, 1987) have also been emphasized (Blanchard et 
al., 2010). A summary of some of the criticisms of the 
PANSS are displayed in Box 2 below. For example the PANSS 
is exclusively reliant upon behaviour observed during the 
process of the interview as well as the carer's perspective; 
thus the ratings are devoid of the individual with 
schizophrenia perspective (Blanchard et al., 2010). 
Particularly troublesome is the lack of perspective that can 
be provided by the client in response to experiential 
deficits (Blanchard et al., 2010; Forbes et al., 2010). Overall 
Blanchard and colleague's (2010) article highlighted the 
limitations of the previously mentioned measures of 
negative symptoms. Specifically that overall the 
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instruments are out-dated and do not reflect the 
contemporary understanding and current empirical 
findings pertaining to negative symptoms (Blanchard et al., 
2010). 
Box 2. Criticism of the PANSS
Criticisms of the PANSS
The clinical implications of the PANSS scores are unclear 
(Leucht et al., 2005).
The clinical meaning of the response cut-off scores employed 
in clinical trials is also unclear due to the aforementioned issue 
(Lancon et al., 1998; Leucht et al., 2005).
Key conceptual limitations. For example individual items 
reflect several conceptually distinct domains (Blanchard et al., 
2010).
Behavioural measurement of experiential deficits (Blanchard 
et al., 2010).
Uncertain factor structure (Lancon et al., 1998).
The shortcomings of existing instruments summarised 
above is in accordance with the National Institute of 
Mental Health (NIMH) consensus statement on negative 
symptoms suggestion for the development of a new 
measure of negative symptomology in schizophrenia 
(Kirkpatrick et al., 2006; Blanchard et al., 2010). As the 
current instruments were impeding advancements in the 
treatment of negative symptoms (Forbes et al., 2010). 
As such a panel of experts convened and collaborated to 
develop a new measure of negative symptoms to 
overcome the shortcomings of the existing measures 
(Forbes et al., 2010; Horan et al., 2011).  It quickly became 
apparent that two instruments were required to remedy 
the current void that existed in the measurement of 
negative symptoms specifically a longer more detailed 
instrument as well as a brief concise instrument suitable for 
clinical trials (Kirkpatrick et al., 2011). Thus the CAINS 
(Forbes et al., 2010; Horan et al., 2011) and the Brief 
Negative Symptom Scale (BNSS: Kirkpatrick et al., 2011; 
Strauss et al., 2012) were developed to meet both of the 
aforementioned challenges respectively. 
The CAINS was developed to measure the five domains of 
negative symptoms espoused by the NIMH consensus 
statement on negative symptoms specifically; anhedonia, 
asociality, avolition, alogia and blunted affect (Forbes et al., 
2010; Horan et al., 2011). However Forbes and colleagues 
(2010) note that the latent structure of negative symptoms 
remains undetermined.  The development of the CAINS 
also sought to overcome the reliance on behavioural and 
performance deficits that existed in the current scales thus 
neglecting experiential deficits that can be considered the 
core of the negative symptom construct (Forbes et al., 
2010). Thus the CAINS incorporates measures of 
experiential deficits (Forbes et al., 2010; Horan et al., 
2011).  Further the CAINS is in line with current empirical 
research on motivation and hedonic experience in 
schizophrenia; as it includes measures of both anticipatory 
and consummatory pleasure (Strauss et al., 2011; Forbes et 
al., 2010; Horan et al., 2011). Recently Barch (2013) 
suggested that use of instruments such as the CAINS assists 
with integrating our current understanding of affective 
neuroscience into the assessment of schizophrenia. 
The initial results from the early development and 
validation study of the CAINS showed overall support for 
the feasibility and validity of the instrument (Forbes et al., 
2010). However there were issues pertaining to the 
measurement of the intensity of hedonic experience in a 
population with vocabulary impediments and limited 
speech output (Forbes et al., 2010).  Furthermore there 
were also issues evident in the measurement of asociality 
specifically concerning how best to integrate the 
information about different social relationships (family, 
romantic and friendships) to improve the consistency of 
the scale (Forbes et al., 2010).
A factor analysis of preliminary CAINS data; has indicated a 
two factor structure to the negative symptom dimension 
(Horan et al., 2011), namely; an experiential factor and an 
expressive factor. With the experiential factor, being 
composed of the symptoms of; avolition, anhedonia and 
asociality and the expressive factor comprised of; blunted 
affect (affective flattening) and alogia (Horan et al., 2011).  
Horan and colleagues (2011) concluded that the CAINS is 
displaying promising potential as a measure for the 
assessment of negative symptoms.  
Although the CAINS is displaying promise not all individuals 
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with schizophrenia have negative symptoms and as such 
assessment by the full CAINS is not always feasible and 
pragmatic (Park et al., 2012). With methods that can 
quickly and efficiently screen patients that may require 
further assessment being both practical and efficient. As 
such Park and colleagues (2012) recently developed and 
trialled at brief self-report version of the CAINS (CAINS-SR). 
The results indicated that the experience subscale was 
psychometrically sound whereas the expression subscale 
exhibited poorer psychometric properties (Park et al., 
2012). Nonetheless the authors concluded that the 
preliminary results indicated the potential of the CAINS-SR 
with further work and validation (Park et al., 2012). 
In addition to the development of the CAINS and the 
CAINS-SR the original expert panel sought to develop a 
concise measure of negative symptoms; specifically a 
measure that would be appropriate for use in both 
inpatient and outpatient clinical trials and sensitive to 
change over time (Kirkpatrick et al., 2011). Thus the Brief 
Negative Symptom Scale (BNSS) was developed 
(Kirkpatrick et al., 2011; Strauss et al., 2012). Following 
from the CAINS the BNSS also sought to measure the five 
domains of negative symptoms, to employ a distinction 
between anticipatory and consummatory experience of 
pleasure as well as a differentiation between internal 
experiences and behaviour (Kirkpatrick et al., 2011). 
Further in addition to being concise; so the measure is 
feasible for use in large multi-centre clinical trials, 
Kirkpatrick and colleagues (2011) also aimed for the items 
to be cross-culturally valid and the measure to be suitable 
for use in other trials (such as epidemiological and 
psychological research). 
The BNSS in addition to measuring the five domains of 
negative symptoms specified by the original NIMH 
consensus statement on negative symptoms (Kirkpatrick et 
al., 2006) also incorporates a measure of distress 
(Kirkpatrick et al., 2011; Strauss et al., 2012). The measure 
of distress or lack of normal distress is included in an 
attempt to differentiate between those that are suffering 
from primary and secondary negative symptoms 
(Kirkpatrick et al., 2011). However further study is required 
to ascertain whether the item meaningfully differentiates 
between the two aforementioned populations (Kirkpatrick 
et al., 2011). 
Similar to the CAINS the BNSS was also found to have a two 
factor structure in Kirkpatrick and colleague's (2011) 
preliminary study. Recently Strauss and colleague's (2012) 
conducted a study to further test the factor structure of the 
BNSS. The results also indicated a two factor structure 
similar to the CAINS with one factor reflecting amotivation 
and pleasure and the other factor indicative of emotional 
expression (Strauss et al., 2012). 
In sum it is clearly apparent that recent efforts have seen 
the development and as such advancement in the 
assessment and measurement of negative symptoms. 
However additional research is necessary to further test 
and validate the psychometric properties of the newly 
developed measures coupled with further delineation of 
the boundaries of the negative symptom construct. 
Moreover efforts need to be made to consolidate upon the 
gains accomplished through the development of new 
measures for the assessment of negative symptoms. Key 
challenges in the area of the assessment of negative 
symptoms are detailed in Table 3 below.
The Treatment of Negative Symptoms
Currently there exists no agreed upon, empirically founded 
efficacious treatment for enduring (or primary) negative 
symptoms in schizophrenia (Kreyenbuhl et al., 2010). With 
most antipsychotic trials generally focusing on positive 
symptoms as the primary outcome measure (Tarrier & 
Wykes, 2004), and few assessing the overall reduction in 
negative symptomology and even fewer evaluating the 
effects on the symptoms independently. As such the PORT 
recommendations for the treatment of schizophrenia do 
not make any recommendations regarding the treatment 
of negative symptoms as to date no pharmacological or 
psychological treatment has been found to be consistently 
effective in the treatment of negative symptomology 
(Kreyenbuhl et al., 2010).
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Although both first and second generation antipsychotics 
have generally been highly effective in the treatment of 
positive symptomology they are minimally effective in the 
treatment of the negative domains of schizophrenia 
(Tandon, Nasrallah & Keshavn, 2010). First generation anti-
psychotics or conventional neuroleptic treatments have 
demonstrated negligible efficacy in the treatment of 
negative symptoms (Kelley, Haas, & van Kammen, 2008; 
Tandon, Nasrallah & Keshavan, 2010). Some second 
generation or atypical antipsychotics have demonstrated 
small effect sizes for the treatment of negative symptoms 
in clinical trials (Buchanan et al., 2007; Kelley, Haas, & van 
Kammen, 2008). However it remains unclear whether this 
reduction in negative symptoms is indicative of a reduction 
of secondary negative symptoms through reducing 
positive and depressive symptoms. Tandon, Nasrallah and 
Keshavan (2010) argue that much of the effect of 
antipsychotics upon negative symptoms is resultant from a 
reduction of psychotic symptoms thus targeting secondary 
negative symptoms not enduring primary negative 
symptoms. Further they ascertain that antipsychotics have 
no demonstrable efficacy against primary negative 
symptoms or deficit syndrome (Kirkpatrick et al., 2006; 
Tandon, Nasrallah & Keshavan, 2010). 
Similarly a recent meta-analysis indicated that the 
augmentation of antipsychotic therapy with an anti-
depressant was more effective than an antipsychotic alone 
in the treatment of negative symptoms (Singh et al., 2010). 
Thus the addition of the anti-depressant may be targeting 
Challenge Research / Action Required Implications
Consistency in the assessment Adoption of the new measures Facilitate the comparative evaluation of 
of negative symptoms (CAINS, BNSS) to assess negative different research studies and aid in the 
symptoms both in research and translation of research into clinical practice.
clinical practice.
Psychometric validation of the new Clarify and validate the psychometric Advancement of the field of negative
measures of negative symptoms properties of the CAINS and BNSS. symptoms research through the provision 
of psychometrically sound measures of 
negative symptoms.
Differentiation of primary and Test the efficacy of distress in delineating Delineation of the difference between 
secondary negative symptoms between primary and secondary primary and secondary negative symptoms
negative symptoms. will assist with the development of
Theorise and test other modes for the treatments to target primary negative
delineation between primary and symptoms. 
negative symptoms.
secondary negative symptoms and/or depressive 
symptoms (masked as negative symptoms) as oppose to 
primary enduring negative symptoms. Further in addition 
to antipsychotic therapy several other pharmacological 
strategies have been evaluated for the treatment of 
negative symptoms with some success thus far according 
to Tandon, Nasrallah and Keshavan (2010). Agents that 
stimulate the NMDA glutamate receptor in combination 
with antipsychotics have demonstrated some efficacy in 
the amelioration of negative symptoms (Tandon, Nasrallah 
& Keshavn, 2010). Further treatments that target the 
metabotropic glutamate receptors have also shown some 
success (Tandon, Nasrallah & Keshavn, 2010).
Recently Noroozian and colleagues (2013) tested the 
efficacy of the augmentation of risperidone treatment with 
tropisetron an anti-emetic drug for chemotherapy-induced 
and postoperative emesis for the treatment of primary 
negative symptoms. The results indicated that the 
tropisetron addition to treatment improved the primary 
negative symptoms of individuals with chronic stable 
schizophrenia. Thus the preliminary results support the 
efficacy of this addition to risperidone and further research 
should be conducted to verify theses preliminary results.
Despite the lack of empirical data, clinical guidelines 
indicate the most effective treatment for schizophrenia 
generally is a continued care approach incorporating 
antipsychotic medication and psychosocial intervention 
such as cognitive behavioural therapy, social skills training, 
family interventions and supported employment (Lehman, 
Lieberman, Dixon, & et al., 2004; Mojtabai, Nicholson, & 
Carpenter, 1998). However, real world studies in hospital 
and community settings demonstrate that this rarely 
occurs (Drake, Bond, & Essock, 2009; Mojtabai et al., 2009).  
Furthermore even when combined pharmacological and 
psychological treatment is offered; participation of 
individuals with prominent negative symptoms may be 
difficult to facilitate and less efficacious due to the inherent 
nature of negative symptoms (Whittington, Barnes & 
Kendall, 2010). 
A variety of psychosocial individual and family treatment 
programs have been developed and trialled for their ability 
to reduce symptoms (in conjunction with antipsychotic 
treatment) and have demonstrated modest effects in 
comparison to treatment as usual for negative symptoms 
(Klingberg et al., 2011; Pfammater, Junghan, & Brenner, 
2006; Thorup et al., 2005). Recently Staring, ter Huurne 
and van der Gaag (2013) in a small pilot study found a 
cognitive behavioural therapy treatment aimed at 
targeting negative symptoms to be modestly effective in 
reducing negative symptomology; therefore further 
research is needed.  However, the delivery of these 
services to community patients is hindered by financial, 
workforce and regulatory constraints within mental health 
systems. In addition to pharmacological and psychological 
interventions for the treatment of negative symptoms 
repetitive transcranial magnetic stimulation (rTMS) has 
also been trialled and is demonstrating some promise for 
the reduction of negative symptoms (Dlabac-de Lange, 
Knegtering & Aleman, 2010; Tandon, Nasrallah & 
Keshavan, 2010).
In sum it is apparent that largely negative symptoms 
remain untreatable; especially primary negative 
symptoms. As such concerted efforts need to be made to 
develop both pharmacological and psychological 
inventions that will reduce not only secondary negative 
symptoms but more importantly primary negative 
symptoms; due to the high level of functional impairment 
that such symptomology imposes. Akin to this challenge is 
the need to be able to differentiate between primary and 
secondary negative symptoms in order to advance 
treatment prospects. Recently Bell and colleagues' (2013) 
based upon the results of their empirical study 
recommended that separate treatments both 
pharmacological and psychosocial, be developed for 
negative symptoms and social cognition.   Similarly Strauss 
and colleagues' (2013) recently conducted a study 
assessing whether negative symptoms are multi or uni-
factorial. The results of their study indicated two separate 
domains and unique negative symptom profiles; in 
accordance with the domains measured by the BNSS and 
CAINS. Therefore they recommended that future studies 
aiming to develop pharmacological treatments for 
negative symptoms should attempt to treat these domains 
of negative symptomology separately. As without reducing 
the heterogeneity of negative symptoms; attempts to 
develop and treat negative symptoms will remain 
challenged (Strauss et al., 2013). 
As reviewed above it is apparent that some novel 
approaches such as agents that target the glutamate 
receptors and rTMS are demonstrating some success in the 
treatment of negative symptoms. As such further work is 
needed to both advance these novel approaches as well as 
clarify the negative symptoms they are targeting (primary 
or secondary) as well as the negative symptom domains 
that they are effective in reducing. Thus due to the extent 
of the dearth of knowledge in this area no specific 
recommendations can be made for future research. Rather 
efforts need to be made generally to develop and test 
treatments both pharmacological and psychological for the 
treatment of primary negative symptoms.
Conclusion :
Important progress in research and translational research 
in particular has influenced practice in the treatment of 
schizophrenia in general. However the issues outlined in 
this paper above highlight the pressing need for research 
within the area of negative symptoms. Not only should 
research focus on the uncertainties in the negative 
symptom construct, the assessment of negative symptoms 
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as well as their treatment but efforts should be made also 
to minimise the gap between evidence based intervention 
and health service delivery (Drake & Essock, 2009). 
Schizophrenia is a multifactorial and complex disorder, and 
no discipline has the skills, capacity and resources to fully 
address the challenges outlined above in order to improve 
the understanding and treatment of primary negative 
symptomology  in  sch izophren ia .   Therefore  
multidisciplinary collaborative research is necessary to 
address the challenges evident pertaining to negative 
symptoms. As the area requires research that can only be 
conducted through the collaborative involvement and 
information sharing of scientists from various disciplines, 
along with health professionals from the community as 
well as mental health consumers. Although the process of 
collaboration is not simple, with a number of significant 
barriers that inhibits the collaborative process. Efforts need 
to be made to overcome these barriers to address the 
dearth of knowledge regarding the nature, assessment and 
treatment of the negative symptoms in schizophrenia and 
hence improve the quality of life of individuals with 
schizophrenia who experience primary negative 
symptoms.
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